Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-016/26
A61K-039/395
C07K-016/28
A61K-039/00
출원번호
US-0822651
(2015-08-10)
등록번호
US-10011656
(2018-07-03)
발명자
/ 주소
Freeman, Gordon J.
Ahmed, Rafi
Jones, Timothy D.
Carr, Francis J.
Gregson, James P.
출원인 / 주소
EMORY UNIVERSITY
대리인 / 주소
Morrison & Foerster LLP
인용정보
피인용 횟수 :
0인용 특허 :
47
초록▼
The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activi
The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
대표청구항▼
1. A method of reactivating exhausted T cells, comprising contacting a population of T cells, wherein at least some T cells express PD-L1, with an effective amount of a composition comprising an isolated antibody or an antigen-binding fragment thereof, wherein the isolated antibody, or an antigen-bi
1. A method of reactivating exhausted T cells, comprising contacting a population of T cells, wherein at least some T cells express PD-L1, with an effective amount of a composition comprising an isolated antibody or an antigen-binding fragment thereof, wherein the isolated antibody, or an antigen-binding fragment thereof, comprises: a) a heavy chain variable region sequence comprising the three CDRs with the sequences of SEQ ID NOs: 13-15; and/orb) a light chain variable region sequence comprising the three CDRs with the sequences of SEQ ID NOs:16-18, and wherein the isolated antibody, or antigen-binding fragment thereof, binds to a PD-L1 protein having the amino acid sequence of SEQ ID NO: 4, and the isolated antibody, or antigen-binding fragment thereof, is chimeric, humanized, composite, or human. 2. The method of claim 1, wherein the antibody or an antigen-binding fragment thereof, comprises: a) a heavy chain variable region sequence comprising the three CDRs with the sequences of SEQ ID NOs: 13-15; andb) a light chain variable region sequence comprising the three CDRs with the sequences of SEQ ID NOs:16-18. 3. The method of claim 2, wherein the antibody or an antigen-binding fragment thereof, comprises: a) a heavy chain variable region sequence selected from the group consisting of SEQ ID NOs: 34-38, or a sequence with at least about 95% homology to a heavy chain sequence selected from the group consisting of SEQ ID NOs: 34-38; andb) a light chain variable region sequence selected from the group consisting of SEQ ID NOs: 39-42, or a sequence with at least about 95% homology to a light chain sequence selected from the group consisting of SEQ ID NOs: 39-42. 4. The method of claim 1, wherein the antibody or an antigen-binding fragment thereof, comprises: a) a heavy chain variable region sequence selected from the group consisting of SEQ ID NOs: 34-38, or a sequence with at least about 95% homology to a heavy chain sequence selected from the group consisting of SEQ ID NOs: 34-38; and/orb) a light chain variable region sequence selected from the group consisting of SEQ ID NOs: 39-42, or a sequence with at least about 95% homology to a light chain sequence selected from the group consisting of SEQ ID NOs: 39-42. 5. The method of claim 4, wherein the antibody or an antigen-binding fragment thereof, comprises: a) a heavy chain variable region sequence selected from the group consisting of SEQ ID NOs: 34-38; and/orb) a light chain variable region sequence selected from the group consisting of SEQ ID NOs: 39-42. 6. The method of claim 5, wherein the antibody or an antigen-binding fragment thereof, comprises: a) a heavy chain variable region sequence selected from the group consisting of SEQ ID NOs: 34-38; andb) a light chain variable region sequence selected from the group consisting of SEQ ID NOs: 39-42. 7. The method of claim 6, wherein the antibody or an antigen-binding fragment thereof, comprises: a) a heavy chain variable region sequence comprising SEQ ID NO: 35 or 37; andb) a light chain variable region sequence comprising SEQ ID NO: 39, 40 or 42. 8. The method of claim 2, wherein the antibody or an antigen-binding fragment thereof, comprises: a) a heavy chain variable region sequence comprising SEQ ID NO: 35 or 37, or a sequence with at least about 95% homology to a heavy chain sequence comprising SEQ ID NO: 35 or 37; andb) a light chain variable region sequence comprising SEQ ID NO: 39, 40 or 42, or a sequence with at least about 95% homology to a light chain sequence comprising SEQ ID NO: 39, 40 or 42. 9. The method of claim 1, wherein the isolated antibody or antigen-binding fragment thereof inhibits the binding of an antibody comprising a heavy chain variable region comprising the sequence of SEQ ID NO:78 and a light chain variable region comprising the sequence of SEQ ID NO:79 to Fc-PD-L1. 10. The method of claim 1, wherein the isolated antibody or antigen-binding fragment thereof inhibits PD-L1-mediated PD-1 signaling. 11. The method of claim 1, wherein the step of contacting is performed in vitro, ex vivo, or in vivo.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (47)
Freeman, Gordon J.; Ahmed, Rafi; Jones, Timothy D.; Carr, Francis J.; Gregson, James P., Anti-PD-L1 antibodies and uses therefor.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Peter S. Mezes ; Ruth A. Richard ; Kimberly S. Johnson ; Jeffrey Schlom ; Syed V. S. Kashmiri ; Liming Shu ; Eduardo A. Padlan, Humanized anti-tag-72 monoclonal antibodies using human subgroup 4 kappa light chains.
La Zor Clair G. (13054 Rose St. Cerritos CA 90701), Instrument for locating faults in aircraft passenger reading light and attendant call control system.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Loughrey Helen C. (Vancouver CAX) Cullis Pieter R. (Vancouver CAX) Bally Marcel B. (Bowen Island CAX) Choi Lewis S. (Burnaby CAX), Method for protein-liposome coupling.
Johnson Kevin Stuart,GBX ; Winter Gregory Paul,GBX ; Griffiths Andrew David,GBX ; Smith Andrew John Hammond,GBX ; Waterhouse Peter Michael,AUX, Methods for producing members of specific binding pairs.
Winter Gregory Paul,GBX ; Johnson Kevin Stuart,GBX ; Griffiths Andrew David,GBX ; Smith Andrew John Hammond,GBX, Methods for producing members of specific binding pairs.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Honjo Tasuku (Kyoto JPX) Ishida Yasumasa (Newton MA) Shinohara Takashi (Kyoto JPX), Peptide related to human programmed cell death and DNA encoding it.
Surani Azim M. (Cambridge GB3) Neuberger Michael S. (Cambridge GB3) Bruggemann Marianne (Cambridge GB3), Production of antibodies from transgenic animals.
Hoogenboom Hendricus R. J. M. (Cambridge GBX) Baier Michael (Frankfurt DEX) Jespers Laurent S. A. T. (Tervuren BEX) Winter Gregory P. (Cambridge GBX), Production of chimeric antibodies - a combinatorial approach.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.